PPI in the Joint Funding Scheme

1:1

PPI is integrated throughout the Joint Funding Scheme. There are specific questions set out in the application form on PPI. In addition, at the Review Panel meeting, PPI is reviewed in the applications and a PPI rating contributes to the consensus panel score. It is therefore important to think about PPI from the very start of planning a research project and submitting an application to the Joint Funding Scheme.

HRCI has produced three case studies of PPI excellence in Joint Funding Scheme applications. The case studies outline the PPI plans and activities the applicants had laid out.  You can read them below and we thank the applicants and the HRCI members that they submitted their proposals to, for allowing us to share their excellent plans.

You might also be interested in

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.
The 2026 Open Academy x ERDERA Schools in Barcelona brought patient advocates and early-career researchers together for practical training on medicines development, translational research and meaningful participation in rare disease research.
From 25–28 May in Barcelona, the EURORDIS-led Open Academy x ERDERA Schools will bring patient advocates and early-career researchers together for four days of rare disease training, exchange and peer learning.
Children, Young People and Family Involvement and Engagement Strategy 2024-2029